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thnic Disparity in
ntracranial Hemorrhage
mong Anticoagulated
atients With Atrial Fibrillation
n Answer in Search of a Question?*
odney H. Falk, MD, FRCP, FACC
oston, Massachusetts
troke due to intracranial hemorrhage (ICH) carries a
igher morbidity and mortality than ischemic stroke, and it
as been estimated that among persons 45 to 64 years of
ge, 8% to 12% of ischemic strokes and 37% to 38% of
emorrhagic strokes result in death within 30 days (1). The
isk of ICH is increased among patients receiving heparin or
arfarin, and the mortality of anticoagulant-associated ICH
s approximately double that of spontaneous ICH (1–4).
trial fibrillation (AF) is an independent risk factor for
schemic stroke. It increases stroke risk about 5-fold, and
his risk is significantly reduced by warfarin.
See page 309
In the last decade, based on robust clinical trials, there has
een an increasing use of warfarin for prevention of isch-
mic stroke, resulting in a reduction in the incidence of
F-associated ischemic stroke. However, complication
ates in clinical trials do not always translate into clinical
ractice. In a survey in the greater Cincinnati area between
988 and 1999, Flaherty et al. (5) reported an increase in
nticoagulant-associated ICH from 5% of all patients with
CH in 1988 to 17% in 1999. This was accompanied by an
pproximately 4-fold increase in warfarin use, and the
uthors attributed the rise in ICH to increasing warfarin
se, predominantly among patients with AF. On the basis
f such data, it has been estimated that approximately 12%
o 24% of intracerebral bleeds are warfarin-related and that
s many as 10,000 anticoagulant-related intracerebral hem-
rrhages occur annually in the U.S. (2–7).
Editorials published in the Journal of American College of Cardiology reflect the views
f the authors and do not necessarily represent the views of JACC or the American
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epartment of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts.In this issue of the Journal, Shen et al. (8) report on the
revalence of ICH among 18,867 patients, hospitalized for
he first time with AF and followed for a median of
pproximately 3 years. The study was retrospective, and
iagnosis was based on the International Classification of
iseases (ICD)-9 codes 430 to 432, which include both
ntracerebral and subarachnoid hemorrhage. During follow-
p, 58.4% took warfarin for at least part of the time. One
undred seventy-five spontaneous ICHs occurred, the ma-
ority of them in patients who were taking warfarin when
he bleed occurred. Although there was no difference in the
revalence of ICH among racial groups who were not
eceiving warfarin, nonwhite patients receiving warfarin had
significantly higher risk of ICH, with a hazard ratio,
ompared with whites, of 2.05 for blacks, 2.06 for Hispan-
cs, and 4.1 for Asians. The findings of this study warrant
areful examination, because they have the potential to
odify practice and, if the results are incorrectly interpreted,
ny change in practice could be detrimental to patient care.
o understand their significance, several questions need to
e addressed. For example, are the findings related to
veranticoagulation in minorities due to increased warfarin
ensitivity or is the increased ICH rate with warfarin in
inorities a function of their greater risk of ICH regardless
f warfarin therapy? And, if minorities have a greater ICH
isk with warfarin, might this reflect a higher prevalence of
ntracranial pathology or is it a feature of a greater preva-
ence of risk factors for ICH such as hypertension? Finally,
hould these results affect the prescribing of warfarin in
inorities, particularly for Asians, who had the highest rate
f this devastating condition?
Genetic variations play a role in determining the main-
enance dose of warfarin and, among patients with muta-
ions that result in a low warfarin maintenance dose,
veranticoagulation during the initial phases of warfarin
reatment is quite common (9). Rieder et al. (10) estimated
hat 21% to 25% of the maintenance dose of warfarin can be
xplained by variance in the gene-encoding vitamin K
poxide reductase complex 1. Five common haplotypes were
dentified, 2 of which resulted in the need for a lower
arfarin dose. Haplotypes predictive of a low maintenance
ose of warfarin were present in 35% of whites compared
ith 89% of Asians but only 14% of blacks; these findings
ave been subsequently confirmed in populations attending
nticoagulation clinics in several different areas of the world
9,11–14). Warfarin sensitivity, partly mediated by genetic
ariation, is associated with an increased bleeding risk. This
isk clusters in the early period of therapy, when excessively
igh international normalized ratio (INR) measurements
ight occur and greatly lessens during maintenance therapy
nce a therapeutic INR is achieved (9). Thus genetic
ifferences in warfarin sensitivity would be expected to
anifest themselves as differences in early bleeding rates. In
he current study, reference to the authors’ figure demon-
trates that, rather than a cluster of bleeding risk early after
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ersisted over several years. Data on anticoagulation inten-
ity are presented and do not suggest that overanticoagula-
ion accounted for excess ICH in minorities. Indeed, among
lacks, there was a tendency toward underanticoagulation.
hus, although genetic variation might explain Asian sen-
itivity to warfarin, it would not account for excessive ICH
ates in the Asian population and would certainly not
xplain the increased risk in blacks.
Hypertension is a major risk factor for ICH, and the risk of
CH is related to hypertension severity and consistency of
lood pressure control (15–18). Blacks have a higher preva-
ence of hypertension than whites, and hypertension in this
opulation might be more severe and more difficult to control.
n the current study, 77.5% of the population had hyperten-
ion, but the black population had the highest prevalence. The
ature of the study did not allow the severity of hypertension to
e assessed, and hypertension was analyzed as a dichotomous
ariable, so it is conceivable that blacks had both a higher
revalence and more severe hypertension, potentially explain-
ng some of their risk. However, there is inadequate informa-
ion to be certain, and the precise role of poorly controlled
ypertension remains intriguing but uncertain.
Cerebral amyloid angiopathy (CAA) is characterized by the
eposition of congophilic amyloid beta protein in cortical and
eptomeningeal vessels (3,19,20) and is associated with lobar
emorrhage in elderly patients. Patients with CAA have a
-fold increase in warfarin-associated intracranial bleeding,
nd several gene polymorphisms are associated with both the
resence and severity of this condition (19). The authors do
ot indicate whether there was a predominance of lobar
emorrhage (which would suggest CAA), but other studies
ave addressed this issue. In a study in northern Manhattan,
lacks and Hispanics were found to have an increased risk of all
ypes of ICH, with nonlobar hemorrhage predominating (6),
nd in an autopsy series of Chinese patients, the prevalence of
AA was found to be much lower than expected in whites,
espite a higher incidence of intracerebral hemorrhage in this
opulation (21). Thus CAA is unlikely to explain the ethnic
ifferences in the current study.
None of the aforementioned mechanisms give a satisfactory
nswer to the findings in this study. Therefore, rather than
ocus the question on why warfarin might have caused an
ncreased ICH risk in minorities, it is worthwhile stepping
ack and asking whether ethnic variation in ICH occurs in the
bsence of warfarin. If so, then the results might well be
xplained by an increased overall ICH risk among warfarin-
reated patients regardless of ethnicity. In the present study,
inorities with AF did not have a statistically significant excess
CH risk unless they were using warfarin. This might suggest
hat the drug is the culprit rather than the existence of intrinsic
nterethnic variations in ICH prevalence that are exaggerated
y anticoagulation. However, extensive data in published
eports suggest that this is not the case. Age standardized
ortality rates in the U.S. between 1995 and 1998 for ischemictroke, subarachnoid hemorrhage, and intracerebral hemor-hage were all higher among blacks than whites, and death
ates from intracerebral hemorrhage but not ischemic stroke
as higher among Asians and Pacific islanders than among
hites (22). In a much larger study than the current one, also
rom Kaiser Permanente of California, black patients had a
elative risk of intracerebral hemorrhage of 1.9 compared with
hites, and Asians had a relative risk of 1.6 (23). Although
nformation is not available about the rhythm in these patients
r their anticoagulant use, this was a relatively young popula-
ion, and it is unlikely that many were using anticoagulants.
inally, in a recently published study of a similar number of
nticoagulant-associated ICH, almost one-half of whom had
F, Flaherty et al. (4) found no evidence of excess warfarin-
elated ICH risk in black patients compared with whites.
The risk of ischemic stroke is high among most patients
ith AF, and it would require overwhelmingly convincing
ata to result in a recommendation to withhold warfarin in
inorities with AF. The present study does not offer such
ata, but the findings do underscore the importance of
eveloping an approach to therapy that should include a
onsideration of ethnicity when choosing a dose of warfarin
o initiate therapy. In addition, the data underscore the
ecessity for a vigorous approach to treating risk factors for
CH, particularly hypertension, which might be more com-
on and more severe in minority populations.
eprint requests and correspondence: Dr. Rodney H. Falk,
epartment of Cardiology, Harvard Vanguard Medical Associ-
tes, 133 Brookline Avenue, Boston, Massachusetts 02215.
-mail: rfalk@partners.org.
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